Sign in or create an account to add this stock to your watchlist.
Exa Corporation develops, sells and supports simulation software and services that manufacturers use in design and engineering processes. The Company focuses primarily on the ground transportation market, including manufacturers in the passenger vehicle, highway truck, off-highway vehicle and train markets, as well as their suppliers. Its product, PowerFLOW, is a software solution for simulating fluid flow problems, including aerodynamics, thermal management and aeroacoustics, or wind noise. PowerFLOW uses its Digital Physics technology that enables it to predict fluid flows. PowerFLOW directly simulates unpredictable turbulent scales. The PowerFLOW software suite includes the simulation engine and grid generation engine, along with pre- and post-processing software products. The software is delivered in client/server architecture, or through its cloud-based offering, ExaCLOUD. With the ExaCLOUD solution, various client features and functions are accessed through a Web browser.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryApplication Software
SectorN/A
SymbolNASDAQ:EXA
CUSIP30061450
Phone+1-781-6768500
Debt
Debt-to-Equity Ratio0.01
Current Ratio1.06
Quick Ratio1.06
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$72.58 million
Price / Sales5.04
Cash Flow$0.2132 per share
Price / Cash113.69
Book Value$1.29 per share
Price / Book18.79
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-1,130,000.00
Net Margins-15.10%
Return on Equity-62.82%
Return on Assets-18.57%
Miscellaneous
Employees345
Outstanding Shares15,100,000
EXA (NASDAQ:EXA) Frequently Asked Questions
What is EXA's stock symbol?
EXA trades on the NASDAQ under the ticker symbol "EXA."
How were EXA's earnings last quarter?
Exa Corp (NASDAQ:EXA) posted its quarterly earnings data on Wednesday, May, 24th. The technology company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.04. The technology company earned $16.56 million during the quarter, compared to the consensus estimate of $16.56 million. EXA had a negative net margin of 15.10% and a negative return on equity of 62.82%. The company's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) EPS. View EXA's Earnings History.
What price target have analysts set for EXA?
4 equities research analysts have issued twelve-month price targets for EXA's stock. Their predictions range from $24.25 to $24.25. On average, they anticipate EXA's stock price to reach $24.25 in the next year. View Analyst Ratings for EXA.
Who are EXA's key executives?
EXA's management team includes the folowing people:
- John J. Shields III, Independent Chairman of the Board (Age 76)
- Stephen A. Remondi, President, Chief Executive Officer, Director (Age 50)
- Richard F. Gilbody, Chief Financial Officer (Age 55)
- Hudong Chen Ph.D., Senior Vice President, Chief Scientific Officer (Age 58)
- Suresh Sundaram, Senior Vice President, Products and Marketing
- James E Hoch, Senior Vice President - Software Development (Age 50)
- Joel F. Dube, Principal Accounting Officer, Vice President - Finance
- Jean-Paul Roux, Vice President - European Operations (Age 51)
- Robert D. Burke, Independent Director (Age 60)
- Mark E. Fusco, Independent Director (Age 52)
Has EXA been receiving favorable news coverage?
Media stories about EXA stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. EXA earned a coverage optimism score of 0.15 on Accern's scale. They also gave media stories about the technology company an impact score of 46.02 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of EXA?
Shares of EXA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EXA's stock price today?
One share of EXA stock can currently be purchased for approximately $24.24.
How big of a company is EXA?
EXA has a market capitalization of $363.92 million and generates $72.58 million in revenue each year. EXA employs 345 workers across the globe.
How can I contact EXA?
EXA's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The technology company can be reached via phone at +1-781-6768500 or via email at [email protected]
MarketBeat Community Rating for EXA (EXA)
MarketBeat's community ratings are surveys of what our community members think about EXA and other stocks. Vote "Outperform" if you believe EXA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXA will underperform the S&P 500 over the long term. You may vote once every thirty days.
EXA (NASDAQ:EXA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for EXA in the last 12 months. Their average twelve-month price target is $24.25, suggesting that the stock has a possible upside of 0.04%. The high price target for EXA is $24.25 and the low price target for EXA is $24.25. There are currently 4 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $24.25 | $24.25 | $20.6250 | $20.6250 |
| Price Target Upside: | 0.04% upside | 0.29% upside | 14.70% downside | 14.70% downside |
EXA (NASDAQ:EXA) Consensus Price Target History
EXA (NASDAQ:EXA) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
EXA (NASDAQ:EXA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
EXA (NASDAQ EXA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.53%
Institutional Ownership Percentage: 74.37%
EXA (NASDAQ EXA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/26/2017 | Soros Fund Management Llc | Major Shareholder | Buy | 14,119 | $16.58 | $234,093.02 | |  |
| 9/25/2017 | Soros Fund Management Llc | Major Shareholder | Buy | 700 | $16.15 | $11,305.00 | | |
| 9/21/2017 | Soros Fund Management Llc | Major Shareholder | Buy | 15,489 | $15.99 | $247,669.11 | | |
| 9/18/2017 | Soros Fund Management Llc | Major Shareholder | Buy | 53,502 | $15.49 | $828,745.98 | | |
| 9/13/2017 | Soros Fund Management Llc | Major Shareholder | Buy | 159,500 | $14.46 | $2,306,370.00 | | |
| 6/1/2017 | John J Shields | Director | Sell | 1,000 | $13.89 | $13,890.00 | 53,078 | |
| 5/1/2017 | John J Shields | Director | Sell | 1,000 | $13.75 | $13,750.00 | 54,078 | |
| 4/3/2017 | John J Shields | Director | Sell | 1,000 | $12.80 | $12,800.00 | 55,078 | |
| 3/1/2017 | John J Shields | Director | Sell | 1,000 | $15.74 | $15,740.00 | 56,078 | |
| 2/1/2017 | John J Shields | Director | Sell | 1,000 | $15.60 | $15,600.00 | 57,078 | |
| 1/3/2017 | John J Shields | Director | Sell | 1,000 | $15.33 | $15,330.00 | 58,078 | |
| 12/20/2016 | Hudong Chen | Insider | Sell | 3,000 | $16.00 | $48,000.00 | 119,656 | |
| 12/20/2016 | James E Hoch | VP | Sell | 12,000 | $16.00 | $192,000.00 | 153,694 | |
| 12/1/2016 | John J Shields | Director | Sell | 1,000 | $15.00 | $15,000.00 | 59,078 | |
| 11/1/2016 | John J Shields | Director | Sell | 1,000 | $14.00 | $14,000.00 | 60,078 | |
| 10/7/2016 | Wayne D Mackie | Director | Buy | 10,565 | $14.91 | $157,524.15 | 69,723 | |
| 10/6/2016 | Fidelity Non-Profit Management | Major Shareholder | Sell | 1,200,000 | $14.72 | $17,664,000.00 | 905,640 | |
| 10/3/2016 | John J Shields | Director | Sell | 1,000 | $16.03 | $16,030.00 | 61,078 | |
| 9/1/2016 | John J Shields | Director | Sell | 1,000 | $15.62 | $15,620.00 | 62,778 | |
| 8/1/2016 | John J Shields | Director | Sell | 2,000 | $14.37 | $28,740.00 | 64,078 | |
| 7/25/2016 | John J Shields | Director | Sell | 4,699 | $13.96 | $65,598.04 | 65,078 | |
| 7/1/2016 | Stephen A Remondi | CEO | Sell | 10,000 | $14.45 | $144,500.00 | 356,974 | |
| 6/6/2016 | Stephen A Remondi | CEO | Sell | 4,001 | $11.52 | $46,091.52 | 369,974 | |
| 6/3/2016 | Stephen A Remondi | CEO | Sell | 5,999 | $11.84 | $71,028.16 | 375,361 | |
| 5/4/2016 | Stephen A Remondi | CEO | Sell | 10,000 | $13.07 | $130,700.00 | 383,732 | |
| 5/3/2016 | Stephen A Remondi | CEO | Sell | 3,363 | $13.09 | $44,021.67 | 383,732 | |
| 5/2/2016 | Stephen A Remondi | CEO | Sell | 3,242 | $13.20 | $42,794.40 | 383,732 | |
| 4/4/2016 | Stephen A Remondi | CEO | Sell | 10,000 | $12.94 | $129,400.00 | 393,120 | |
| 3/21/2016 | Hudong Chen | VP | Sell | 20,000 | $12.01 | $240,200.00 | 74,426 | |
| 3/14/2016 | James E Hoch | VP | Sell | 8,000 | $11.50 | $92,000.00 | 96,464 | |
| 3/1/2016 | Stephen A Remondi | CEO | Sell | 10,000 | $10.64 | $106,400.00 | 401,974 | |
| 2/24/2016 | Hudong Chen | VP | Sell | 10,000 | $10.61 | $106,100.00 | 105,926 | |
| 2/2/2016 | Stephen A. Remondi | CEO | Sell | 10,000 | $10.76 | $107,600.00 | 406,974 | |
| 1/8/2016 | James E Hoch | VP | Sell | 4,000 | $11.50 | $46,000.00 | 104,464 | |
| 1/5/2016 | Stephen A. Remondi | CEO | Sell | 10,000 | $11.57 | $115,700.00 | 416,974 | |
| 1/5/2016 | Wayne D Mackie | Director | Buy | 5,000 | $11.58 | $57,900.00 | 65,148 | |
| 1/4/2016 | Stephen A. Remondi | CEO | Sell | 2,754 | $11.46 | $31,560.84 | 416,974 | |
| 12/31/2015 | James E. Hoch | VP | Sell | 4,000 | $11.50 | $46,000.00 | 108,464 | |
| 12/22/2015 | Stephen A. Remondi | CEO | Sell | 10,000 | $11.00 | $110,000.00 | 426,974 | |
| 12/21/2015 | Richard F. Gilbody | CFO | Buy | 10,000 | $10.92 | $109,200.00 | 20,000 | |
| 12/16/2015 | Wayne D. Mackie | Director | Buy | 3,375 | $10.44 | $35,235.00 | 54,713 | |
| 12/15/2015 | Wayne D. Mackie | Director | Buy | 10,000 | $10.08 | $100,800.00 | 54,713 | |
| 12/14/2015 | Wayne D. Mackie | Director | Buy | 3,175 | $10.09 | $32,035.75 | 54,713 | |
| 11/3/2015 | Stephen A. Remondi | CEO | Sell | 10,000 | $9.68 | $96,800.00 | 436,974 | |
| 10/7/2015 | Stephen A. Remondi | CEO | Sell | 10,000 | $10.02 | $100,200.00 | 446,974 | |
| 10/6/2015 | Stephen A. Remondi | CEO | Sell | 6,623 | $10.00 | $66,230.00 | 446,974 | |
| 10/5/2015 | Stephen A. Remondi | CEO | Sell | 800 | $10.15 | $8,120.00 | 446,974 | |
| 9/2/2015 | Stephen A Remondi | CEO | Sell | 10,000 | $10.51 | $105,100.00 | 456,974 | |
| 7/6/2015 | Stephen A Remondi | CEO | Sell | 10,000 | $11.06 | $110,600.00 | | |
| 6/11/2015 | John J Shields | Director | Sell | 4,600 | $11.36 | $52,256.00 | | |
| 6/9/2015 | John J Shields | Director | Sell | 5,400 | $11.50 | $62,100.00 | | |
| 6/4/2015 | Stephen A Remondi | CEO | Sell | 10,000 | $10.85 | $108,500.00 | | |
| 5/5/2015 | Stephen A Remondi | CEO | Sell | 8,884 | $10.94 | $97,190.96 | | |
| 4/16/2015 | Wayne D Mackie | Director | Buy | 12,000 | $10.79 | $129,480.00 | | |
| 4/2/2015 | Stephen A Remondi | CEO | Sell | 10,000 | $11.64 | $116,400.00 | | |
| 3/9/2015 | Stephen A Remondi | CEO | Sell | 6,423 | $10.00 | $64,230.00 | | |
| 3/6/2015 | Stephen A Remondi | CEO | Sell | 3,577 | $10.16 | $36,342.32 | | |
| 2/9/2015 | Stephen A Remondi | CEO | Sell | 4,802 | $10.23 | $49,124.46 | | |
| 2/4/2015 | Stephen A Remondi | CEO | Sell | 5,198 | $10.22 | $53,123.56 | | |
| 2/3/2015 | Stephen A Remondi | CEO | Sell | 1,489 | $10.21 | $15,202.69 | | |
| 2/2/2015 | Stephen A Remondi | CEO | Sell | 2,109 | $10.24 | $21,596.16 | | |
| 1/9/2015 | Stephen A Remondi | CEO | Sell | 10,000 | $10.79 | $107,900.00 | | |
| 12/22/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $11.12 | $111,200.00 | | |
| 11/6/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $9.97 | $99,700.00 | | |
| 10/1/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $11.30 | $113,000.00 | | |
| 9/2/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $12.02 | $120,200.00 | | |
| 8/1/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $9.25 | $92,500.00 | | |
| 7/1/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $11.11 | $111,100.00 | | |
| 6/17/2014 | Jean-Paul Roux | VP | Buy | 2,000 | $9.44 | $18,880.00 | | |
| 6/9/2014 | John William Sr Poduska Sr | Director | Buy | 2,793 | $8.90 | $24,857.70 | | |
| 6/4/2014 | Stephen A Remondi | CEO | Sell | 10,000 | $9.12 | $91,200.00 | | |
| 5/1/2014 | Stephen Remondi | CEO | Sell | 10,000 | $10.90 | $109,000.00 | 182,359 | |
| 4/10/2014 | Stephen Sarno | CFO | Buy | 1,000 | $11.98 | $11,980.00 | 16,000 | |
| 4/4/2014 | John William Sr Poduska, Sr. | Director | Buy | 1,600 | $12.71 | $20,336.00 | 47,207 | |
| 4/4/2014 | Stephen Remondi | CEO | Sell | 2,500 | $12.72 | $31,800.00 | 192,359 | |
| 4/3/2014 | Stephen Remondi | CEO | Sell | 7,500 | $13.13 | $98,475.00 | 194,859 | |
| 4/1/2014 | John William Sr Poduska, Sr. | Director | Buy | 1,000 | $13.31 | $13,310.00 | 46,607 | |
| 3/28/2014 | John William Sr Poduska, Sr. | Director | Buy | 6,300 | $13.39 | $84,357.00 | 45,607 | |
| 3/25/2014 | James Hoch | VP | Sell | 1,300 | $15.75 | $20,475.00 | 35,541 | |
| 3/4/2014 | Stephen Remondi | CEO | Sell | 10,000 | $14.75 | $147,500.00 | 52,359 | |
| 1/6/2014 | Stephen Remondi | CEO | Sell | 10,000 | $13.31 | $133,100.00 | 72,359 | |
| 12/20/2013 | Stephen Remondi | CEO | Sell | 10,000 | $13.08 | $130,800.00 | 82,359 | |
| 12/17/2013 | John William Sr Poduska, Sr. | Director | Buy | 4,607 | $13.53 | $62,332.71 | 41,607 | |
| 10/2/2013 | Jean-Paul Roux | VP | Buy | 2,000 | $15.17 | $30,340.00 | 130,289 | |
| 10/2/2013 | Stephen A Remondi | CEO | Sell | 10,000 | $15.14 | $151,400.00 | | |
| 9/18/2013 | John William Sr Poduska, Sr. | Director | Buy | 11,821 | $15.62 | $184,644.02 | 39,000 | |
| 9/13/2013 | John William Sr Poduska, Sr. | Director | Buy | 6,170 | $13.96 | $86,133.20 | 31,009 | |
| 9/4/2013 | Stephen A Remondi | CEO | Sell | 10,000 | $13.78 | $137,800.00 | | |
| 8/2/2013 | Stephen Remondi | CEO | Sell | 10,000 | $11.50 | $115,000.00 | 112,359 | |
| 7/12/2013 | John William Sr Poduska Sr | Director | Buy | 5,009 | $10.26 | $51,392.34 | | |
| 7/2/2013 | Stephen A Remondi | CEO | Sell | 10,000 | $10.61 | $106,100.00 | | |
| 6/3/2013 | Stephen A Remondi | CEO | Sell | 10,000 | $8.32 | $83,200.00 | | |
| 4/9/2013 | John William Sr Poduska Sr | Director | Buy | 6,000 | $7.55 | $45,300.00 | | |
| 4/8/2013 | Stephen P Sarno | Insider | Buy | 5,000 | $7.50 | $37,500.00 | | |
| 4/5/2013 | Edmond L Furlong | CFO | Buy | 10,000 | $7.55 | $75,500.00 | | |
| 4/4/2013 | John F Smith Jr | Director | Buy | 4,000 | $8.10 | $32,400.00 | | |
| 2/1/2013 | Stephen A Remondi | CEO | Sell | 10,000 | $9.81 | $98,100.00 | | |
| 1/17/2013 | Edmond L Furlong | CFO | Buy | 15,998 | $9.95 | $159,180.10 | | |
| 1/11/2013 | Edmond L Furlong | CFO | Buy | 5,973 | $9.57 | $57,161.61 | | |
| 1/9/2013 | Stephen P Sarno | Insider | Buy | 10,000 | $9.34 | $93,400.00 | | |
| 1/4/2013 | John William Sr Poduska Sr | Director | Buy | 20,000 | $9.73 | $194,600.00 | | |
(Data available from 1/1/2013 forward)
EXA (NASDAQ EXA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Innoplexus Releases New Study Examining Consumer Perceptions of Pharmaceutical Companies
www.prnewswire.com - May 17 at 7:49 AM |
| The 30-Year View: Examining the Future of Gold
www.prnewswire.com - May 17 at 3:36 AM |
 | Here Is the Exact Amount of Money You Need to Be Considered ‘Wealthy’ in America
finance.yahoo.com - May 16 at 2:46 PM |
| Cloud Native Computing Foundation Announces Launch of Certified Kubernetes Application Developer (CKAD) Exam
www.prnewswire.com - May 2 at 3:48 AM |
| Exact Sciences to participate in two investor conferences during May
www.prnewswire.com - May 1 at 6:08 AM |
 | Why Exact Sciences Is Soaring Today
www.fool.com - April 27 at 1:43 PM |
 | Exact Sciences Q1 revenue up 87%; shares up 1% after hours
seekingalpha.com - April 26 at 4:32 PM |
| Kathy's Urgent Care Offering More Affordable DOT/CDL Physical Exams
www.prnewswire.com - April 23 at 11:32 AM |
| Study Examines Maternal Metabolic Factors and Early-Onset Puberty
www.prnewswire.com - April 16 at 3:58 AM |
 | EXA (EXA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:53 PM |
| EXA (EXA) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 1 at 2:04 PM |
| Examobile SA.’s (WSE:EXA) Earnings Dropped -54.75%, How Did It Fare Against The Industry?
finance.yahoo.com - March 29 at 10:24 AM |
| The Most Valuable Asset in Real Estate Could Be Your Photographer
www.prnewswire.com - March 28 at 4:08 AM |
 | Glytec Announces Appointment of Ed Furlong as Chief Operating Officer
www.bizjournals.com - March 22 at 10:11 AM |
 | Exactly when to buy plane tickets to get the best deals
www.cnbc.com - March 21 at 10:22 AM |
| Dr. Shad Morris, DMD, Sets Example for Sleep Dentists Nationally in Former NFL Player Health Assessment
www.prnewswire.com - March 21 at 4:39 AM |
 | Death of the Mall? Greatly Exaggerated, Says Big Money
www.wsj.com - March 19 at 5:49 PM |
| Study Examines how Pharmaceutical Industry is Navigating New Scientific Publications Landscape
www.prnewswire.com - March 9 at 7:08 PM |
| Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations hearing "Examining U.S. Public Health Preparedness for and Respons
www.prnewswire.com - March 8 at 12:23 PM |
| AT&T Connectivity Powers Dictum Health's Virtual Exam Room
www.prnewswire.com - March 5 at 9:52 AM |
| Best Practices, LLC Report Examines How the Pharmaceutical Industry is Utilizing the Role of Medical Affairs to Enhance Payer Interactions
www.prnewswire.com - March 2 at 6:48 PM |
| New Book Examines How Jesus of Nazareth Became Jesus the Prophet
www.prnewswire.com - March 1 at 8:46 AM |
| Point of Care Diagnostics: Good But Not Exaggerated Growth Next Five Years, Report
www.prnewswire.com - February 28 at 11:13 PM |
 | Exact Sciences (EXAS) a Buy at $44.37
investorplace.com - February 28 at 11:36 AM |
| New Exam Prep Tool Boosts National Mortgage Licensing Exam Success
www.prnewswire.com - February 22 at 8:51 AM |
| Definition of what’s actually an 'assault weapon' is a highly contentious issue
www.cnbc.com - February 21 at 8:34 PM |
| Atlas API Training Develops Unique Audio Flash Cards to Complement Their Online Exam Prep Courses for Advanced Petrochemical Industry API Certifications
www.prnewswire.com - February 21 at 5:12 AM |
| More Students Than Ever Are Participating And Succeeding In Advanced Placement
www.prnewswire.com - February 21 at 1:27 AM |
| Radars And Weapons Global Market Report 2018
www.prnewswire.com - February 12 at 11:51 AM |
| ExactRead -- Fengtao Software's New Technology to Correct Read Errors Caused by Optical Drives
www.prnewswire.com - February 11 at 3:28 AM |
| Bloomberg Law Litigation Report Examines Drugmaker's Unprecedented Patent Deal with American Indian Tribe
www.prnewswire.com - February 8 at 10:00 AM |
 | ROHM's New Boost Converter Provides 1.3x Longer Battery Life
feeds.benzinga.com - January 30 at 12:10 PM |
| Exact Sciences under modest pressure on new report from long-term bear Citron, shares down 3%
seekingalpha.com - January 25 at 2:34 PM |
| Colorectal Cancer Alliance-Funded Research among First to Examine Relationship between Colon Microbiota and Colorectal Cancer
www.prnewswire.com - January 23 at 6:23 AM |
| Exact Sciences under pressure on potential CRC blood screening test; shares down 9%
seekingalpha.com - January 17 at 11:23 AM |
| Head to Head Survey: Attunity (ATTU) and EXA (EXA)
www.americanbankingnews.com - January 16 at 7:56 PM |
| Exa Corp (EXA) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 16 at 4:02 AM |
| Exact Sciences Announces Upsize and Pricing of $600 Million of 1.0% Convertible Senior Notes Due 2025
www.prnewswire.com - January 11 at 10:20 PM |
| 3 Slides That Paint a Great Picture for Exact Sciences' Future
www.fool.com - January 10 at 9:19 AM |
| Global IoT Markets Dataset & Report 2017: Technologies & Market Forecasts up to 2030 - Examination of Market Trends in 14 Major Verticals
www.prnewswire.com - January 8 at 12:32 PM |
| Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017
www.prnewswire.com - January 7 at 2:10 PM |
| The Cryptocurrency Market Isn't Fair, Which Is Exactly Why It's So Successful
www.fool.com - January 6 at 12:53 PM |
| UPDATE - CCEI Offers No-Cost Online Course Examining The Mentoring Process: Developing Professionalism from Within
feeds.benzinga.com - January 3 at 12:26 PM |
| Pesquera Exalmar S.A.A. Announces Exchange Offer And Consent Solicitation For Any And All Of Its 7.375% Senior Notes Due 2020
www.prnewswire.com - December 22 at 8:13 PM |
| Exa Corp (EXA) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 22 at 3:58 AM |
| New National Study Examines 2017 U.S. Physician Employment and Compensation Growth
www.prnewswire.com - December 19 at 5:19 AM |
 | République owners opening restaurant in downtown L.A.'s historic Herald Examiner building
www.latimes.com - December 7 at 6:49 AM |
| 500,000 New Biometric Driver's Licenses per Month
www.prnewswire.com - December 6 at 5:52 AM |
| 500.000 novas carteiras de motorista com identificação biométrica por mês
www.prnewswire.com - December 6 at 5:52 AM |
| Sino-British Academic Exchanges Take Step Forward in English Assessment
www.prnewswire.com - December 6 at 4:02 AM |
EXA (NASDAQ:EXA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
EXA (NASDAQ:EXA) Income Statement, Balance Sheet and Cash Flow Statement
EXA (NASDAQ EXA) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
